Current status of excision repair cross complementing-group 1 (ERCC1) in cancer

L Gossage, S Madhusudan - Cancer treatment reviews, 2007 - Elsevier
Cisplatin, carboplatin and oxaliplatin are some of the most widely used anti-cancer agents in
solid tumours. The cytotoxicity of platinating agents is directly related to their ability to cause …

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer

X Wu, J Gu, TT Wu, SG Swisher, Z Liao… - Journal of clinical …, 2006 - ascopubs.org
Purpose Understanding how specific genetic variants modify drug action pathways may
provide informative blueprints for individualized chemotherapy. Methods We applied a …

ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells

RA Britten, D Liu, A Tessier… - … journal of cancer, 2000 - Wiley Online Library
Cisplatin is a valuable adjuvant to radiotherapy for the treatment of cervical cancer. Because
the advantage of combining cisplatin with radiotherapy is likely to be attributable to additive …

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX–bevacizumab or FOLFIRI–bevacizumab: results …

JC Bendell, TS Bekaii-Saab, AL Cohn… - The …, 2012 - academic.oup.com
Abstract Background. The Avastin® Registry: Investigation of Effectiveness and Safety
(ARIES) study is a prospective, community-based observational cohort study that evaluated …

[HTML][HTML] ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

HJ Jun, MJ Ahn, HS Kim, SY Yi, J Han, SK Lee… - British journal of …, 2008 - nature.com
The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting
role in the nucleotide excision repair pathway and is associated with resistance to platinum …

Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric …

K Ott, K Herrmann, F Lordick, H Wieder, WA Weber… - Clinical Cancer …, 2008 - AACR
Purpose: We prospectively evaluated the predictive value of positron emission tomography
using fluorine-18 fluorodeoxyglucose (FDG-PET) for in vivo testing of chemosensitivity in …

A synthetic suicide riboswitch for the high-throughput screening of metabolite production in Saccharomyces cerevisiae

SW Lee, MK Oh - Metabolic engineering, 2015 - Elsevier
Artificial devices such as the synthetic riboswitch have shown potential to introduce
unnatural phenotypic perturbation because its synthetic traits are distinct from that of innate …

Genetic polymorphisms and treatment response in advanced non-small cell lung cancer

D Su, S Ma, P Liu, Z Jiang, W Lv, Y Zhang, Q Deng… - Lung cancer, 2007 - Elsevier
BACKGROUND: Genetic polymorphisms involved in DNA repair and apoptosis are
suspected to influence patient response to cancer treatment. To evaluate the effect of …

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based …

S Ota, G Ishii, K Goto, K Kubota, YH Kim, M Kojika… - Lung cancer, 2009 - Elsevier
PURPOSE: The aim of this study was to determine the prognostic value of expression of ATP
binding cassette (ABC) transporter proteins and DNA repair gene proteins by …

The paradigm of mutant p53-expressing cancer stem cells and drug resistance

Y Shetzer, H Solomon, G Koifman… - …, 2014 - academic.oup.com
It is well accepted that expression of mutant p53 involves the gain of oncogenic-specific
activities accentuating the malignant phenotype. Depending on the specific cancer type …